Affymetrix, Inc.  

(Public, NASDAQ:AFFX)   Watch this stock  
Find more results for AFFX
+0.10 (0.71%)
Feb 12 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 14.01 - 14.09
52 week 8.28 - 14.15
Open 14.05
Vol / Avg. 737,339.00/4.28M
Mkt cap 1.13B
P/E 101.55
Div/yield     -
EPS 0.14
Shares 79.97M
Beta 0.19
Inst. own 107%
May 12, 2016
Affymetrix Inc Annual Shareholders Meeting (Estimated) - 12:00PM EDT - Add to calendar
Feb 5, 2016
Q4 2015 Affymetrix Inc Earnings Release (Estimated)
Nov 19, 2015
Affymetrix Inc at Jefferies Autumn Global Healthcare Conference
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '15) 2014
Net profit margin -6.17% -1.10%
Operating margin -4.64% 0.61%
EBITD margin - 10.86%
Return on average assets -3.94% -0.77%
Return on average equity -6.41% -1.41%
Employees 1,200 -
CDP Score - -


3420 Central Expy
SANTA CLARA, CA 95051-0703
United States - Map
+1-408-7315000 (Phone)
+1-408-7315380 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
Transcripts - SeekingAlpha


Affymetrix, Inc. is a provider of life science products and molecular diagnostic products that enable parallel analysis of biological systems at the gene, protein and cell level. The Company sells its products to genomic research centers, academic institutions, government and private laboratories, as well as pharmaceutical, diagnostic and biotechnology companies. The Company maintains sales and distribution operations across the United States, Europe, Latin America and Asia. It operates in two business segments: Affymetrix Core and eBioscience. Affymetrix Core focuses on the development, manufacture and commercialization of systems for genetic analysis in the life sciences, agricultural biotechnology (AgBio) and diagnostic industries. eBioscience primarily focuses on the development, manufacture, marketing and distribution of research products in the areas of flow cytometry, immunoassays, microscopic imaging and other protein-based analyses.

Officers and directors

Jami K. Nachtsheim Independent Chairwoman of the Board
Age: 56
Bio & Compensation  - Reuters
Frank R. Witney Ph.D. President, Chief Executive Officer, Director
Age: 61
Bio & Compensation  - Reuters
Gavin Wood Chief Financial Officer, Executive Vice President
Age: 45
Bio & Compensation  - Reuters
Andrew J. Last Ph.D. Chief Operating Officer, Executive Vice President
Age: 55
Bio & Compensation  - Reuters
David Weber Executive Vice President, Chief Commercial Officer
Age: 61
Bio & Compensation  - Reuters
Riccardo Pigliucci Director
Bio & Compensation  - Reuters
Nelson C. Chan Independent Director
Age: 54
Bio & Compensation  - Reuters
Gary S. Guthart Ph.D. Independent Director
Age: 49
Bio & Compensation  - Reuters
Merilee Raines Independent Director
Age: 59
Bio & Compensation  - Reuters
Robert H. Trice Ph.D. Independent Director
Age: 68
Bio & Compensation  - Reuters